BattelinoTDanneTBergenstalRM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593-1603.
4.
GargSKWeinzimerSATamborlaneWV, et al. Glucose outcomes with the in-house use of hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:155-163.
5.
PolonskyWHFisherLHesslerDEdelmanSV.Development of a new measure for assessing glucose monitoring device-related treatment satisfaction and quality of life. Diabetes Technol Ther. 2015;17:657-663.
6.
IturraldeETanenbaumMLHanesSJ, et al. Expectations and attitudes of individuals with type 1 diabetes after using a hybrid closed loop system. Diabetes Educ. 2017;43:223-232.
7.
AleppoGWebbKM.Integrated insulin pump and continuous glucose monitoring technology in diabetes care today: a perspective of real-life experience with the MiniMed™ 670G hybrid closed loop system. Endocr Pract. 2018;24:684-692.
8.
SoupalJPetruzelkovaLFlekacM, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18:532-538.
9.
EnglerRRouthTLLucisanoJY.Adoption barriers for continuous glucose monitoring and their potential reduction with a fully implanted system: results from patient preference surveys. Clin Diabetes. 2018;36:50-58.
10.
KrugerDFEdelmanSVHinnenDAParkinCG.Reference guide if integrating continuous glucose monitoring into clinical practice. Diabetes Educ. 2019;45:3S-20S.
